NasdaqGS - Delayed Quote USD

Lexicon Pharmaceuticals, Inc. (LXRX)

0.6266
-0.0332
(-5.03%)
At close: May 30 at 4:00:02 PM EDT
0.6110
-0.02
(-2.49%)
After hours: May 30 at 7:50:01 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
31,213
31,081
1,204
139
298
Cost of Revenue
615
616
85
0
0
Gross Profit
30,598
30,465
1,119
139
298
Operating Expense
208,061
227,582
172,869
100,899
87,388
Operating Income
-177,463
-197,117
-171,750
-100,760
-87,090
Net Non Operating Interest Income Expense
162
-3,286
-5,369
-1,184
-668
Pretax Income
-177,301
-200,403
-177,119
-101,944
-87,758
Tax Provision
--
--
--
--
0
Net Income Common Stockholders
-177,301
-200,403
-177,119
-101,944
-87,758
Diluted NI Available to Com Stockholders
-177,301
-200,403
-177,119
-101,944
-87,758
Basic EPS
-0.50
--
-0.79
-0.62
-0.60
Diluted EPS
-0.50
--
-0.79
-0.62
-0.60
Basic Average Shares
349,201.7500
--
221,130
165,733
145,652
Diluted Average Shares
349,201.7500
--
221,130
165,733
145,652
Total Operating Income as Reported
-177,463
-197,117
-171,750
-100,760
-87,090
Total Expenses
208,676
228,198
172,954
100,899
87,388
Net Income from Continuing & Discontinued Operation
-177,301
-200,403
-177,119
-101,944
-87,758
Normalized Income
-177,301
-200,403
-177,119
-101,944
-87,758
Interest Income
12,628
12,293
7,732
1,596
134
Interest Expense
12,466
15,579
13,101
2,780
802
Net Interest Income
162
-3,286
-5,369
-1,184
-668
EBIT
-164,835
-184,824
-164,018
-99,164
-86,956
EBITDA
-164,269
-184,290
-163,464
-98,737
-86,664
Reconciled Cost of Revenue
615
616
85
0
0
Reconciled Depreciation
566
534
554
427
292
Net Income from Continuing Operation Net Minority Interest
-177,301
-200,403
-177,119
-101,944
-87,758
Total Unusual Items Excluding Goodwill
--
--
--
0
0
Total Unusual Items
--
--
--
0
0
Normalized EBITDA
-164,269
-184,290
-163,464
-98,737
-86,664
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 4/7/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SGMO Sangamo Therapeutics, Inc.
0.4650
+1.59%
 
CTMX CytomX Therapeutics, Inc.
2.6500
+5.16%
 
CHRS Coherus BioSciences, Inc.
0.7790
-2.87%
 
EYEN Eyenovia, Inc.
1.6700
-7.73%
 
GERN Geron Corporation
1.5200
+2.70%
 
PSTV Plus Therapeutics, Inc.
0.2869
+0.17%
 
MIST Milestone Pharmaceuticals Inc.
1.6200
+1.89%
 
MCRB Seres Therapeutics, Inc.
7.05
-0.56%
 
RIGL Rigel Pharmaceuticals, Inc.
19.20
-1.69%
 
IBRX ImmunityBio, Inc.
2.6600
+2.31%